Last updated: 30 July 2024 at 5:36pm EST

Werner Kroll Net Worth




The estimated Net Worth of Werner Kroll is at least $7.88 Million dollars as of 1 July 2021. Werner Kroll owns over 982 units of QuidelOrtho stock worth over $503,621 and over the last 10 years he sold QDEL stock worth over $6,142,010. In addition, he makes $1,232,050 as Senior Vice President - R&D at QuidelOrtho.

Werner Kroll QDEL stock SEC Form 4 insiders trading

Werner has made over 10 trades of the QuidelOrtho stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 982 units of QDEL stock worth $44,043 on 1 July 2021.

The largest trade he's ever made was exercising 72,528 units of QuidelOrtho stock on 22 May 2020 worth over $1,394,713. On average, Werner trades about 3,128 units every 25 days since 2014. As of 1 July 2021 he still owns at least 11,229 units of QuidelOrtho stock.

You can see the complete history of Werner Kroll stock trades at the bottom of the page.





Werner Kroll biography

Dr. Werner E. Kroll Ph.D. serves as Senior Vice President - R&D of the Company. Prior to joining us, Dr. Kroll was Vice President and Global Head Research and Innovation for Novartis Molecular since 2009. Prior to holding that position, he held a variety of senior positions from 2005 to 2009 at Novartis. Dr. Kroll has also held senior positions at Bayer from 1991 to 2005. Dr. Kroll received his Ph.D. and a Diploma in Chemistry from the University of Marburg.

What is the salary of Werner Kroll?

As the Senior Vice President - R&D of QuidelOrtho, the total compensation of Werner Kroll at QuidelOrtho is $1,232,050. There are 6 executives at QuidelOrtho getting paid more, with Douglas Bryant having the highest compensation of $4,168,770.



How old is Werner Kroll?

Werner Kroll is 63, he's been the Senior Vice President - R&D of QuidelOrtho since 2014. There are 8 older and 18 younger executives at QuidelOrtho. The oldest executive at QuidelOrtho Corporation is Mary Polan, 76, who is the Independent Director.

Insiders trading at QuidelOrtho

Over the last 21 years, insiders at QuidelOrtho have traded over $509,235,797 worth of QuidelOrtho stock and bought 304,015 units worth $10,385,234 . The most active insiders traders include Jack W Schuler, Matthew Strobeck, and Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of $1,246,606. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth $3,078,785.



What does QuidelOrtho do?

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.



What does QuidelOrtho's logo look like?

QuidelOrtho Corporation logo

Complete history of Werner Kroll stock trades at QuidelOrtho

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
1 Jul 2021 Werner Kroll
SVP, Research, and Development
Option 982 $128.60 $126,285
1 Jul 2021
11,229
27 May 2021 Werner Kroll
SVP, Research, and Development
Option 4,376 $121.50 $531,684
27 May 2021
12,495
22 Feb 2021 Werner Kroll
SVP, Research, and Development
Sale 22,902 $166.79 $3,819,825
22 Feb 2021
8,119
3 Aug 2020 Werner Kroll
SVP, Research, and Development
Sale 2,072 $287.48 $595,659
3 Aug 2020
4,599
22 May 2020 Werner Kroll
SVP, Research, and Development
Option 72,528 $19.23 $1,394,713
22 May 2020
8,975
3 Dec 2019 Werner Kroll
SVP, Research, and Development
Sale 22,951 $68.02 $1,561,127
3 Dec 2019
3,795
12 Jun 2018 Werner Kroll
SVP, Research, and Development
Sale 2,500 $66.16 $165,400
12 Jun 2018
16,005
8 Dec 2017 Werner Kroll
SVP, Research, and Development
Option 16,358 $23.41 $382,941
8 Dec 2017
12,976
5 Dec 2017 Werner Kroll
SVP, Research, and Development
Option 13,536 $22.90 $309,974
5 Dec 2017
4,956
6 Nov 2017 Werner Kroll
SVP, Research, and Development
Option 7,565 $22.85 $172,860
6 Nov 2017
10,261


QuidelOrtho executives and stock owners

QuidelOrtho executives and other stock owners filed with the SEC include: